Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target.

Keyphrases

• Mycobacterium Tuberculosis (M. tb) 100%
• Structural Characterization 100%
• Drug Target 100%
• Biochemical Characterization 100%
• Tuberculosis Drugs 100%
• Aspartyl-tRNA Synthetase 100%
• Minimum Inhibitory Concentration 66%
• Single nucleotide Polymorphism 66%
• Resistant mutants 66%
• Fold Increase 33%
• High-throughput Screening 33%
• Transfer RNA (tRNA) 33%
• Overexpressing 33%
• Potent Inhibitor 33%
• Resistant Strains 33%
• Current Treatment 33%
• Multidrug 33%
• Causative Agents 33%
• Cell Targeting 33%
• Whole Cell 33%
• Mortality Rate 33%
• M. Bovis BCG 33%
• Promoter Region 33%
• Treatment Programs 33%
• New Inhibitors 33%
• Inhibitor-1 33%
• Human Pathogens 33%
• Mycobacterium Bovis BCG 33%
• Whole Genome Sequencing 33%
• Target Engagement 33%
• Mycobacterial Growth 33%
• Extensively Drug-resistant 33%
• Pulmonary Tuberculosis 33%
• M. Smegmatis 33%
• Hit-to-lead Optimization 33%
• Mycobacterium Smegmatis 33%

Biochemistry, Genetics and Molecular Biology

• Minimum Inhibitory Concentration 100%
• Single-Nucleotide Polymorphism 100%
• Mycobacterium Bovis BCG 100%
• Transfer RNA 100%
• Aspartic Acid 100%
• Enzyme 50%
• Whole Cell 50%
• Crystal Structure 50%
• High Throughput Screening 50%
• Mortality Rate 50%
• Promoter Region 50%
• Infectious Agent 50%
• Mycobacterium Tuberculosis 50%
• Whole Genome Sequencing 50%
• Mycobacterium Smegmatis 50%

Immunology and Microbiology

• Minimum Inhibitory Concentration 100%
• Mycobacterium Bovis BCG 100%
• Single Nucleotide Polymorphism 100%
• Whole Cell 50%
• Mortality Rate 50%
• Crystal Structure 50%
• Mycobacterium Tuberculosis 50%
• Promoter Region 50%
• High Throughput Screening 50%
• Whole Genome Sequencing 50%
• Human Pathogen 50%
• Smegma 50%
• Mycobacterium Smegmatis 50%